What Pathogenus Consulting does

Pathogenus Consulting Ltd. is a UK-registered private limited consultancy (company number 16206861) that provides specialized advisory services for infectious disease drug and vaccine development. The firm is organized around six integrated service pillars: Clinical Trial Design, Regulatory Affairs, Clinical Oversight and Safety Monitoring, Project and Program Management, Team Leadership and Corporate Efficiencies, and Scientific Advice and Analyses. Its offering spans the development lifecycle from R&D through market authorization, including regulatory interactions with FDA, EMA, TGA, and MHRA, and access to accelerated pathways such as Orphan Drug Designation, Fast Track, PRIME, and ILAP. Documented engagements include Controlled Human Infection study data review, RCT data reanalysis enabling positive investor announcements, and Human Challenge Trial design for cholera and other indications.

The firm serves biotechnology and pharmaceutical companies ranging from start-up biotechs to large pharma, alongside clinical research organizations (CROs) requiring infectious disease operational support. Documented clients include a clinical-stage pharmaceutical company, an Australian intranasal drug developer, a Portuguese diabetic foot ulcer therapeutics firm, and a cholera vaccine developer. Services are delivered through direct engagement by senior team members rather than junior staffing pyramids, positioning the firm as a boutique senior-advisory practice rather than a staffing-led consultancy.

Pathogenus operates a sales-led B2B model with quote-based pricing determined by scope and complexity, generating revenue solely from professional services fees. The firm is led by founder Adrian Wildfire (35+ years in infectious diseases) alongside five other senior professionals with backgrounds at Roche, large CROs, and academic referral hospitals, supported by offices in London, Brussels, Basel, and Amsterdam. The company evolved from the prior iterations CHIMunomics and CHIMagents Ltd. and currently maintains a strategic partnership with US-based Southern Research signed in February 2026. No institutional investors, parent company, or public market presence is evidenced.

Name

Pathogenus Consulting

Legal name

PATHOGENUS CONSULTING LTD.

Website

https://pathogenus.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Short description

Pathogenus Consulting Ltd. provides infectious disease drug and vaccine development consulting — including clinical trial design, regulatory affairs, safety monitoring, and program management — to biotechnology and pharmaceutical companies via senior industry experts across four European offices.

Ownership category

akta.pro rank

Product category

Pharmaceutical & Life Sciences Consulting

NAICS

Management Consulting Services (54161), Other Scientific and Technical Consulting Services (54169)

SIC

Services-Management Consulting Services (8742), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

akta.pro secondary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

Keywords

• Infectious disease consulting
• Clinical trial design
• Regulatory affairs consulting
• Drug development advisory
• Vaccine development consulting

Headquarters

HQ city

City Of London

HQ country

United Kingdom

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Consulting Services: Professional consulting services delivered by former industry leaders and executives, providing expertise in project management, operational and change management, scientific and clinical guidance, and analyses for drug and vaccine development across all stages from R&D to market authorisation.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Pathogenus Consulting provides expert consulting services for drug and vaccine development, with a specialisation in infectious diseases. Services span clinical trial design, regulatory affairs, clinical oversight and safety monitoring, project and program management, team leadership and corporate efficiencies, and scientific advice and analyses. The firm supports clients across the full development lifecycle from R&D to market authorisation, drawing on former pharma and CRO industry leaders to deliver strategic and operational guidance.

Product overview

Pathogenus Consulting Ltd. offers a unified suite of consultancy services for drug and vaccine development, providing integrated support across the development lifecycle from R&D to market authorisation. The portfolio encompasses Clinical Trial Design Services, Regulatory Affairs Services, Clinical Oversight and Safety Monitoring Services, Project and Program Management Services, Team Leadership and Corporate Efficiencies Services, and Scientific Advice and Analyses Services. These services work together as an integrated consultancy offering, with specialists available for project management, operational and change management, scientific and clinical guidance and analyses, enabling clients to navigate complex development programs and regulatory environments.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Trial Design Services Expert guidance on clinical trial design including recommendation of appropriate trial designs (conventional, group-sequential, adaptive, biomarker-based), advice on selection of endpoints and objectives, and optimised interim decisions including stopping rules and sample-size re-estimation. Intended for biotech and pharmaceutical sponsors designing infectious disease clinical studies.
• Regulatory Affairs Services Integrated regulatory strategy consulting for global product development, including interactions with EMA, FDA, TGA, and other regulatory authorities, access to Orphan Drug Designations, and accelerated development pathways such as Fast Track, PRIME, and ILAP. Targeted at biotech and pharma sponsors navigating complex regulatory environments.
• Clinical Oversight and Safety Monitoring Services Expert clinical development oversight including design and implementation of clinical studies (Phases I-IV), expertise in virology and respiratory infections, anti-infective safety assessments, medical evaluation of assets, pharmacovigilance, and epidemiological study design and analysis. Serves sponsors needing senior medical and safety oversight.
• Project and Program Management Services Life sciences project management including project planning, execution, risk management, resource management, regulatory compliance, change management, quality assurance, capital/site facility build projects, clinical development management, manufacturing, and technology transfer. Supports sponsors running complex multi-stage development programs.
• Team Leadership and Corporate Efficiencies Services Building high-performance international leadership teams, divisional and project teams including KOLs, scientists, regulatory, HR, legal, compliance, QA, and operations associates; business development, operational efficiency optimisation, and strategic alliances management. Targets biotech and pharma sponsors needing senior team build-out or operational improvements.
• Scientific Advice and Analyses Services Independent expert advice in translational sciences, defining Mechanism(s) of Action and Efficacy, assay selection and validation guidance, and assistance in interpreting pre-clinical and clinical datasets for regulatory compliance. Aimed at biotech and pharma sponsors needing expert scientific interpretation of their data.

Quantifiable outcome

• Clinical program rescued from near-abortion due to safety finding; attribution clarified as co-medication rather than study drug, enabling program continuation
• +2 more outcomes

Named customers4 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Southern ResearchcoreStrategic or Co-development Partner · 2 February 2026Southern Research and Pathogenus Consulting Ltd. (PCL) signed a partnership agreement on 02-Feb-2026. The partnership combines Southern Research's research capabilities with Pathogenus's infectious disease expertise to deliver enhanced clinical development services to clients.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• ICON plc: Large global CRO providing clinical trial design and execution services across therapeutic areas including infectious disease; comparable as a competing provider of clinical development services to biotech and pharma clients.
• Medpace Holdings: Mid-sized global CRO offering full-service clinical development across therapeutic areas; competes with Pathogenus in clinical trial design and execution for biotech and pharma sponsors.
• Worldwide Clinical Trials: Global mid-sized CRO with strong presence in infectious disease and vaccine trials, including human challenge studies; serves as a comparable provider of clinical and regulatory services in the ID space.
• Parexel International: Large global CRO with deep clinical development, regulatory affairs and biopharmaceutical services capabilities; serves as a broad incumbent alternative for biotech/pharma seeking clinical and regulatory support.
• Pharmaron: Global CRO/CDMO offering preclinical through clinical development services with growing infectious disease and vaccine capabilities; competes with Pathogenus for integrated development mandates.
• Charles River Laboratories: Global CRO with established infectious disease and vaccine development capabilities, including preclinical and clinical services; competes with Pathogenus for pharma and biotech development mandates.
• IQVIA: World's largest CRO with broad clinical, regulatory and consulting capabilities including infectious disease R&D support; a major incumbent competitor in the clinical development services market Pathogenus addresses.

Emerging players

• KCR: European-headquartered CRO with cross-region clinical development services; comparable as a smaller, regionally-focused peer competing with Pathogenus for European biotech and pharma engagements.
• Richmond Pharmacology: UK-based specialty clinical research organization with Phase I expertise and early-phase trial capabilities; overlaps with Pathogenus's infectious disease clinical design and oversight services in a similar UK base.

Direct peers

• hVIVO plc: Specialty clinical services company focused on human challenge trials and infectious disease clinical research, closely aligned with Pathogenus's CHIM heritage and infectious disease specialty.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/pathogenus-consulting-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pathogenus Consulting